Advertisement

Topics

Dermira Enters into Agreement for Global Rights to Roche’s IL-13 Drug Lebrikizumab

10:13 EDT 9 Aug 2017 | Speciality Pharma Journal

MENLO PARK, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) — Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it has entered into a licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc., a member of the Roche Group (together Roche). Pursuant …

Original Article: Dermira Enters into Agreement for Global Rights to Roche’s IL-13 Drug Lebrikizumab

NEXT ARTICLE

More From BioPortfolio on "Dermira Enters into Agreement for Global Rights to Roche’s IL-13 Drug Lebrikizumab"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...